On World Cancer Day

–having regard to Rule 167(2) of its Rules of Procedure,

A.whereas every year in the EU, 2.7 million people are diagnosed with cancer and a further 1.3 million people lose their lives to it, according to the European Cancer Information System;

B.whereas cancer-related health spending in the EU has more than doubled since 1995 (from EUR 54 billion to EUR 120 billion in 2023), accounting for 6.9 % of total health expenditure in 2023; whereas by 2050, an increase in the number of cancer cases, linked to population ageing, is expected to lead to a 59 % rise in per-capita cancer-related spending in real terms in the current Member States;

C.whereas according to the WHO’s International Agency for Research on Cancer, at least 40 % of all cancer cases could be prevented with effective primary prevention measures; whereas the main risk factors for cancer include tobacco use, alcohol consumption, an unhealthy diet, obesity, a lack of physical activity, endocrine disruptors, environmental exposures, including to PFAS, occupational exposures, air pollutant concentrations, exposure to ultraviolet radiation, and infections (e.g. the hepatitis B and C viruses and some types of human papillomavirus);

D.whereas, despite progress, significant inequalities persist between and within Member States in terms of prevention, screening, early diagnosis, treatment, survivorship and palliative care;

E.whereas according to the report by the Organisation for Economic Co-operation and Development and the Commission entitled ‘Delivering High Value Cancer Care – European Cancer Inequalities Registry Analytical Report’, cancer diagnoses among younger people (aged between 15 and 49) have risen more substantially among younger women than among younger men; whereas a growing number of people, particularly younger women, are living with a cancer diagnosis that requires treatment and monitoring, which is placing sustained pressure on health and social care services;

F.whereas cancer is one of the leading causes of premature death among women globally, with 2.3 million women dying prematurely from cancer each year; whereas 1.5 million of these deaths could be prevented through primary prevention or early detection, and a further 800 000 could be averted if all women had access to optimal cancer care;

G.whereas systemic gender inequalities persist in cancer care, research and policymaking, influencing priorities, funding and the focus of studies, thereby perpetuating gender disparities in health outcomes;

H.whereas rare cancers account for more than one in five cancer diagnoses in the EU and are associated with delayed detection, limited treatment options, scarce clinical expertise and major cross‑border inequalities; whereas addressing rare cancers requires strong EU‑level coordination, dedicated funding and reinforced European Reference Networks;

I.whereas Europe’s Beating Cancer Plan provides a strong framework, but its implementation requires renewed political commitment, funding and coordination;

J.whereas on 16 February 2022, it adopted a resolution on strengthening Europe in the fight against cancer;

1.Marks World Cancer Day, observed on 4 February, and expresses its solidarity with all patients, survivors, families, healthcare workers and researchers fighting cancer across Europe;

2.Calls on the Commission and the Member States to renew their political commitment to the full implementation of Europe’s Beating Cancer Plan throughout the full period of the 2028-2034 multiannual financial framework (MFF), ensuring consistency, adequate funding and concrete national action, with annual reporting mechanisms and improved transparency on implementation gaps; calls on the Commission to take due account of Member States’ best practices and experiences as part of its efforts to achieve the targets set out in Europe’s Beating Cancer Plan;

3.Regrets the fact that the 2028-2034 MFF does not have a dedicated health budget line; calls for a specific EU health programme, with a dedicated envelope, to protect public health and support patient and civil society participation in policymaking; stresses that dedicated funding is necessary to deliver flagship EU health initiatives that require multiannual continuity and implementation capacity, such as Europe’s Beating Cancer Plan, which needs predictable investment to translate commitments into delivery in practice;

4.Calls on the Commission and the Council to recognise health and cancer care as social investment objectives that can be achieved through investment in national recovery and resilience plans, including support for long-term cancer infrastructure such as vaccination and screening programmes, workforce development and robust oncology data systems;

5.Stresses the importance of fully integrating gender-related differences into cancer research, prevention, screening, diagnosis and treatment; encourages the development and implementation of targeted and evidence-based strategies to ensure effective and equitable access to early detection, timely diagnosis and high-quality cancer care;

6.Stresses that paediatric cancer remains a rare but high-burden disease with major survival and access inequalities across Europe; calls on the Commission and the Member States to enhance EU-level cooperation on and funding for paediatric oncology research, data sharing and clinical trials, to boost drug development and access to innovation for children and adolescents with cancer, to strengthen paediatric and adolescent cancer networks and infrastructure, to ensure timely cross-border referral to specialised centres through the European Reference Networks in order to guarantee equitable access to innovative and age-appropriate treatments and diagnostics, and to facilitate comprehensive long-term follow-up care, including psychosocial, educational and social support for children, adolescents and young adults who are survivors and their families;

7.Calls for the promotion of geriatric oncology as a branch that deserves special consideration and funding, and that needs to be enriched by scientific research to ascertain the best treatment and diagnostic methods for older patients;

8.Stresses that patients still face many difficulties in accessing high-quality public healthcare services; calls, therefore, for the creation of high-quality infrastructure for the delivery of treatment, based on EU guidelines and in line with the most recent scientific evidence;

9.Calls for stronger mechanisms to facilitate cross-border access to specialised cancer care and clinical trials, particularly for rare and complex cancers, in full alignment with the Cross-Border Healthcare Directive;

10.Reiterates the need to ensure fair, timely and affordable access to cancer medicines and innovative therapies throughout the EU; notes with concern the persistent disparities among Member States in terms of patient access to such medicines and therapies; notes that this particularly affects smaller markets, even though the medicines and therapies have EU market authorisation; calls on the Commission, in cooperation with the Member States, to facilitate voluntary joint procurement where appropriate, to promote price transparency in line with national competences, to support earlier market entry, and to address unjustified delays between authorisation by the European Medicines Agency and patient access, particularly for life-saving cancer treatments;

11.Calls on the Commission to support the Member States in implementing the Council recommendations on cancer screening and on vaccine-preventable cancers, with a view to helping them to improve the early detection and prevention of cancer;

12.Calls on the Commission to ensure strong alignment and complementarity between Europe’s Beating Cancer Plan and any future European action on diseases, including the Safe Hearts Plan and any action on rare diseases;

13.Stresses that achieving targets on cancer prevention complements the prevention of other non-communicable diseases; emphasises that these targets can be achieved by, among other things, adopting measures to reduce exposure to risk factors such as tobacco products, alcohol consumption, environmental contaminants, air pollutants and harmful materials and substances, such as carcinogenic, mutagenic and reprotoxic substances, including PFAS and endocrine disruptors, and advancing the One Health approach and an exposome agenda;

14.Stresses the importance of tackling health-related disinformation and misinformation, particularly regarding cancer prevention, screening, vaccination and treatment; calls on the Commission and the Member States to strengthen evidence-based public communication, support health literacy and promote cooperation with healthcare professionals, researchers, patient organisations and digital platforms to ensure that citizens have access to reliable, scientifically sound information, while fully respecting freedom of expression;

15.Calls on the Commission to step up its efforts to protect cancer survivors across the EU from financial discrimination, including by effectively promoting the right to be forgotten, and urges the Member States to adopt binding legislation to enshrine this right nationally; insists that the Commission build on the 2023 Consumer Credit Directive to continue strengthening the right of cancer survivors to be forgotten; calls for a harmonised framework that guarantees access for cancer survivors to financial services, including mortgages, loans and insurance; insists that the forthcoming 2026 guidance for financial undertakings be swiftly followed by legislative measures to close remaining gaps, ensuring that no cancer survivor faces discrimination on account of their medical history;

16.Instructs its President to forward this resolution to the Council, the Commission, the governments and parliaments of the Member States, the relevant international organisations and the relevant stakeholders.